Main demographic, hematological, and clinical data from the MDS/MPN cohort
| Variable . | Baseline distribution in the cohort (n = 367) . | |||
|---|---|---|---|---|
| CMML (n = 119) . | aCML (n = 71) . | MDS/MPN-RS-T (n = 71) . | MDS/MPN-U (n = 106) . | |
| Demographics | ||||
| Sex, n (%) | ||||
| Male | 79 (66) | 50 (70) | 27 (38) | 67 (63) |
| Female | 40 (34) | 21 (30) | 44 (62) | 39 (37) |
| Age, years, median (range) | 77 (50-89) | 74 (50-92) | 74 (44-93) | 75 (32-91) |
| Blood counts, median (range) | ||||
| Hb, g/dL | 11.8 (7.0-16.6) | 10.1 (5.8-14.6) | 9.4 (6.0-12.2) | 9.4 (4.9-14.9) |
| WBC count, ×109/L | 16.1 (2.8-86.9) | 44.8 (15.6-325.0) | 6.6 (2.4-19.7) | 27.3 (1.2-202.4) |
| Platelets, ×109/L | 119 (14-1,77) | 102 (60-786) | 564 (454-1,416) | 121 (7-2,276) |
| Neutrophils, ×109/L | 8.2 (0.3-54.7) | 28.53 (3.6-162.5) | 4.0 (1.8-8.6) | 18.2 (0.3-123.5) |
| Monocytes, ×109/L | 4.0 (1.0-95.7) | 0.8 (0.0-17.8) | 0.2 (0-0.7) | 0.7 (0-13.5) |
| Blasts, % | 0 (0-9) | 2 (0-18) | 0 (0-1) | 1 (0-10) |
| Bone marrow features | ||||
| Blasts, median (range) | 6 (0-19) | 1 (0-19) | 2 (0-6) | 2 (0-15) |
| <5%, n (%) | 81 (68) | 54 (76) | 68 (96) | 76 (72) |
| ≥5%, n (%) | 38 (32) | 17 (24) | 3 (4) | 30 (28) |
| Ring sideroblasts, median (range) | 0 (0-18) | 0 (0-14) | 66 (18-97) | 0 (0-84) |
| Cytogenetics | ||||
| Available, n/total n (%) | 119/119 (100%) | 69/71 (97%) | 69/71 (97%) | 102/106 (96%) |
| Normal karyotype, n (%) | 99 (83%) | 40 (58%) | 62 (90%) | 54 (53%) |
| Altered karyotype, n (%) | 20 (17%) | 29 (42%) | 7 (10%) | 48 (47%) |
| +8, n (%) | 6 (5%) | 12 (17%) | 3 (4%) | 26 (25%) |
| Isolated, n | 4 | 9 | 2 | 17 |
| +1 Abnormality, n | 2 | 2 | 1 | 3 |
| In CK, n | 0 | 1 | 0 | 6 |
| −7/del(7q), n (%) | 4 (3) | 4 (6) | 0 (0) | 12 (12) |
| Isolated, n | 3 | 0 | 0 | 5 |
| +1 Abnormality, n | 1 | 1 | 0 | 2 |
| In CK, n | 0 | 3 | 0 | 5 |
| −Y, n (%) | 4 (3) | 1 (1) | 3 (4) | 1 (1) |
| Complex karyotype, n (%) | 0 (0) | 3 (4) | 0 (0) | 12 (12) |
| Treatment, n (%) | ||||
| Cases with treatment information | 103 (87) | 57 (80) | 64 (90) | 86 (81) |
| No treatment | 52 (50) | 18 (32) | 35 (55) | 31 (36) |
| Supportive care | 17 (17) | 3 (5) | 21 (33) | 9 (11) |
| Azacytidine | 11 (11) | 4 (7) | 1 (2) | 6 (7) |
| Cytoreductive treatment | 18 (17) | 30 (53) | 6 (9) | 33 (38) |
| AML-induction therapy | 5 (5) | 2 (3) | 1 (2) | 7 (8) |
| Allogenic SCT | 5 (5) | 5 (9) | 1 (2) | 5 (6) |
| Outcome | ||||
| Cases with follow-up, n (%) | 99 (83) | 56 (79) | 52 (73) | 73 (69) |
| Median follow-up, median mo (range) | 39 (2-112) | 12 (3-98) | 48 (2-163) | 21 (2-182) |
| Leukemic transformation, n (%) | 16/91 (18) | 4/45 (9) | 4/47 (9) | 6/61 (10) |
| OS, median mo (95% CI) | 74 (48-101) | 16 (12-20) | NR | 80 (NR) |
| Variable . | Baseline distribution in the cohort (n = 367) . | |||
|---|---|---|---|---|
| CMML (n = 119) . | aCML (n = 71) . | MDS/MPN-RS-T (n = 71) . | MDS/MPN-U (n = 106) . | |
| Demographics | ||||
| Sex, n (%) | ||||
| Male | 79 (66) | 50 (70) | 27 (38) | 67 (63) |
| Female | 40 (34) | 21 (30) | 44 (62) | 39 (37) |
| Age, years, median (range) | 77 (50-89) | 74 (50-92) | 74 (44-93) | 75 (32-91) |
| Blood counts, median (range) | ||||
| Hb, g/dL | 11.8 (7.0-16.6) | 10.1 (5.8-14.6) | 9.4 (6.0-12.2) | 9.4 (4.9-14.9) |
| WBC count, ×109/L | 16.1 (2.8-86.9) | 44.8 (15.6-325.0) | 6.6 (2.4-19.7) | 27.3 (1.2-202.4) |
| Platelets, ×109/L | 119 (14-1,77) | 102 (60-786) | 564 (454-1,416) | 121 (7-2,276) |
| Neutrophils, ×109/L | 8.2 (0.3-54.7) | 28.53 (3.6-162.5) | 4.0 (1.8-8.6) | 18.2 (0.3-123.5) |
| Monocytes, ×109/L | 4.0 (1.0-95.7) | 0.8 (0.0-17.8) | 0.2 (0-0.7) | 0.7 (0-13.5) |
| Blasts, % | 0 (0-9) | 2 (0-18) | 0 (0-1) | 1 (0-10) |
| Bone marrow features | ||||
| Blasts, median (range) | 6 (0-19) | 1 (0-19) | 2 (0-6) | 2 (0-15) |
| <5%, n (%) | 81 (68) | 54 (76) | 68 (96) | 76 (72) |
| ≥5%, n (%) | 38 (32) | 17 (24) | 3 (4) | 30 (28) |
| Ring sideroblasts, median (range) | 0 (0-18) | 0 (0-14) | 66 (18-97) | 0 (0-84) |
| Cytogenetics | ||||
| Available, n/total n (%) | 119/119 (100%) | 69/71 (97%) | 69/71 (97%) | 102/106 (96%) |
| Normal karyotype, n (%) | 99 (83%) | 40 (58%) | 62 (90%) | 54 (53%) |
| Altered karyotype, n (%) | 20 (17%) | 29 (42%) | 7 (10%) | 48 (47%) |
| +8, n (%) | 6 (5%) | 12 (17%) | 3 (4%) | 26 (25%) |
| Isolated, n | 4 | 9 | 2 | 17 |
| +1 Abnormality, n | 2 | 2 | 1 | 3 |
| In CK, n | 0 | 1 | 0 | 6 |
| −7/del(7q), n (%) | 4 (3) | 4 (6) | 0 (0) | 12 (12) |
| Isolated, n | 3 | 0 | 0 | 5 |
| +1 Abnormality, n | 1 | 1 | 0 | 2 |
| In CK, n | 0 | 3 | 0 | 5 |
| −Y, n (%) | 4 (3) | 1 (1) | 3 (4) | 1 (1) |
| Complex karyotype, n (%) | 0 (0) | 3 (4) | 0 (0) | 12 (12) |
| Treatment, n (%) | ||||
| Cases with treatment information | 103 (87) | 57 (80) | 64 (90) | 86 (81) |
| No treatment | 52 (50) | 18 (32) | 35 (55) | 31 (36) |
| Supportive care | 17 (17) | 3 (5) | 21 (33) | 9 (11) |
| Azacytidine | 11 (11) | 4 (7) | 1 (2) | 6 (7) |
| Cytoreductive treatment | 18 (17) | 30 (53) | 6 (9) | 33 (38) |
| AML-induction therapy | 5 (5) | 2 (3) | 1 (2) | 7 (8) |
| Allogenic SCT | 5 (5) | 5 (9) | 1 (2) | 5 (6) |
| Outcome | ||||
| Cases with follow-up, n (%) | 99 (83) | 56 (79) | 52 (73) | 73 (69) |
| Median follow-up, median mo (range) | 39 (2-112) | 12 (3-98) | 48 (2-163) | 21 (2-182) |
| Leukemic transformation, n (%) | 16/91 (18) | 4/45 (9) | 4/47 (9) | 6/61 (10) |
| OS, median mo (95% CI) | 74 (48-101) | 16 (12-20) | NR | 80 (NR) |
AML, acute myeloid leukemia; CI, confidence interval; Hb, hemoglobin; NR, not reached; SCT, stem cell transplant.